ATLANTA, GA--(Marketwired - Nov 12, 2015) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced the successful negotiation and execution of the Company's second international distribution center agreement to serve the Asia Pacific network of country distributors with Medical Innovators Pty. Ltd., located in Sydney, Australia.

"The distribution center is an additional step in establishing a global footprint for the distribution of the DenerveX™ System. A logical step towards our future plans to further establish additional international distribution centers as we complete distributor agreements in various countries and prepare for the launch of the DenerveX system," commented Patrick Kullmann, President and COO of Medovex.

Manfred Sablowski, Senior Vice President Sales & Marketing continues, "This agreement fits our mission to provide a world-wide distribution channel for our DenerveX System, while serving an important market segment in Asia Pacific."

Medical Innovators Pty. Ltd. is expected to provide distribution support services for the various country distributors throughout the Asia Pacific market for the launch of the DenerveX System.

The DenerveX System is designed to provide relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system. The Company's patented DenerveX System, currently in development and not yet FDA cleared, CE marked or commercially available.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit

Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward- looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information:

Medovex Corp.
Jason Assad